Stock Analysis
Absci Corporation (ABSI) Stock Analysis
Absci Corporation (ABSI) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Absci Corporation (ABSI) currently has an AIQ Score of 53/100, indicating a neutral setup. Momentum is the strongest factor at 85/100. Quality is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ABSI at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $8.45 |
| AIQ Score | 53/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $1.45B |
| P/E Ratio (TTM) | -10.7 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.19 |
| Revenue (Q3 FY2026) | $304K |
| Dividend Yield (TTM) | 0.00% |
| Beta | 3.28 |
| Volume | 5.49M |
| 52-week range | $2.24-$12.54 |
| RSI 14 | 42.01 |
| 50-Day SMA | $9.65 |
| 200-Day SMA | $6.83 |
| Analyst Price Target | $14.50 |
| Next Earnings | — |
ABSIAbsci Corporation
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum85
- Value—
- Quality26
- Risk resilience30
- Sentiment—
ABSI Stock Analysis Summary
Absci Corporation (ABSI) currently has an AIQ Score of 53/100, indicating a neutral setup. Momentum is the strongest factor at 85/100. Quality is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, ABSI has AIQ Score of 53/100 with Momentum base of 85/100 and fading Quality at 26/100. Wait for component alignment before adding exposure.
Momentum (85/100) leads while Quality (26/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -7.50% stock move · ABSI classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ABSI Bullish or Bearish Right Now?
ABSI currently has a neutral overall setup. Momentum is the strongest factor at 85/100, while Quality is weakest at 26/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 85/100.
- - Analyst target implies +71.60% upside from the latest quote.
- - Risk Resilience is weak at 30/100.
- - Technical consensus has more sell votes than buy votes (31 vs 12).
Current Consensus
ABSI's Technical Analysis Consensus is currently Sell, with 12 buy, 3 neutral, and 31 sell votes. ABSI's 14-day RSI is 42.01, which places the stock in a weaker momentum range. ABSI's beta is 3.28, indicating greater market sensitivity than the broad market.
What Changed in ABSI?
The largest recent change in ABSI is Momentum moving down by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the ABSI Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ABSI Decision Framework
Public evidence layers, setup checks, and risk context for Absci Corporation.
Absci Corporation (ABSI) Stock Analysis
Absci Corporation has an AIQ Score of 53/100 in a Neutral regime. Momentum is strongest at 85/100. Beta is 3.28, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ABSI is in a Neutral AIQ regime with score 53/100. |
| Signal Conflict | The primary conflict is that momentum leads at 85/100 while quality lags at 26/100. |
| Factor Evidence | Momentum 85/100 · Quality 26/100 · Risk 30/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 85/100.
Momentum is 85/100 and RSI (14) is 42.0.
ABSI is in a Neutral regime at 53/100.
Risk factor is 30/100 with beta 3.28 and annual volatility 104.15%.
Current conflict: momentum leads at 85/100 while quality lags at 26/100.
ABSI Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ABSI Fundamentals
ABSI valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ABSI Technical Analysis
ABSI technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ABSI Stock Catalysts
Track ABSI earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ABSI Dividend Analysis
ABSI dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ABSI Financial Data
ABSI revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ABSI Risk Analysis
ABSI volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ABSI Stock News
ABSI stock news, market tone, recent headlines, and catalyst context.
ABSI vs Biotechnology Peers
Current peer cohort: ABSI · ABUS · ABVX · ADMA · AGIO. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ABSI Current stock | 53/100 | — | 85/100 | 30/100 | 1.58 | 104.15% | Current |
| ABUS Arbutus Biopharma Corp | 70/100 | 92/100 | 51/100 | 62/100 | -0.09 | 45.89% | ABSI vs ABUS |
| ABVX Abivax S.A. | 35/100 | — | 34/100 | 37/100 | 0.24 | 86.44% | ABSI vs ABVX |
| ADMA ADMA Biologics, Inc. | 78/100 | 80/100 | 91/100 | 56/100 | -0.01 | 58.93% | ABSI vs ADMA |
| AGIO Agios Pharmaceuticals, Inc. | 56/100 | 52/100 | 61/100 | 47/100 | 0.07 | 79.96% | ABSI vs AGIO |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for ABSI: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ABSI
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ABSI
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ABSI Stock FAQ
What is ABSI stock price today?
Absci Corporation's current stock price is $8.45. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ABSI bullish or bearish right now?
ABSI's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ABSI's market cap?
ABSI's market cap is $1.45B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ABSI's current P/E ratio?
ABSI's current P/E ratio is -10.7 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ABSI's RSI?
ABSI's 14-day RSI is 42.01 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ABSI above its 50-day and 200-day moving averages?
ABSI is -12.47% from its 50-day SMA and 23.70% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ABSI's next earnings date?
ABSI's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ABSI pay a dividend?
ABSI's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.